Seqirus, a provider of influenza vaccine, has unveiled plans to build a next-generation A$800m ($584m) influenza vaccine manufacturing facility in Australia.

Using cell-based technology, the new facility will produce influenza vaccines for use in influenza pandemics and seasonal vaccination programmes. It will be supplied to Australia as well as the rest of the world.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The company said that the facility will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

In addition to influenza vaccines, the new facility will also manufacture Seqirus’ adjuvant MF59.

MF59 is a substance that will be added to some vaccines to improve immune response while reducing the amount of antigen required for each vaccine. It will also allow manufacturing more doses more quickly.

The new facility will also produce unique products including antivenom for Australian snakes, spiders and marine creatures, as well as the world’s only human vaccine for Q-Fever.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new facility is expected to commence operations by the mid of 2026.

Previously, the company has signed an agreement with the government of Australian to obtain the ongoing onshore manufacture and supply of influenza pandemic vaccines, anti-venoms and Q-Fever vaccine for more than 10 years.

CSL CEO and managing director Paul Perreault said: “Providing safe and effective influenza vaccines is essential in securing our defences against serious public health threats.

“The facility will be an important addition to our global influenza manufacturing supply chain, incorporating the technology platform used in our Holly Springs, North Carolina facility.

“Cell-based influenza vaccine technology offers many advantages over the existing process including being more scalable and offering faster production – particularly important in the case of influenza pandemics.”

—————————————————————————————————————–

Seqirus to construct influenza vaccine manufacturing facility in Australia. (Credit:Seqirus.)